Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Cogs-Excluding-Depreciation-and-Amortization" stands at 441.02 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Astellas Pharma Inc.'s second quarter result of 138.25 Billion JPY for the item "Cogs Excluding Depreciation and Amortization" represents an increase of 45.79 percent compared to it's first quarter result.
Also, Astellas Pharma Inc.'s second quarter result of 138.25 Billion JPY for the item "Cogs Excluding Depreciation and Amortization" represents an increase of 18.24 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Astellas Pharma Inc.'s second quarter result of 441.02 Billion JPY for the item "Cogs Excluding Depreciation and Amortization" represents an increase of 5.08 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 49.90 percent compared to the value the year prior.
The 1 year change in percent is 49.90.
The 3 year change in percent is 148.33.
The 5 year change in percent is 136.82.
The 10 year change in percent is 61.33.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Cogs Excluding Depreciation and Amortization | 905,699,262,464.00 |
![]() | Johnson & Johnson - Cogs Excluding Depreciation and Amortization | 486,508,953,600.00 |
![]() | AbbVie Inc - Cogs Excluding Depreciation and Amortization | 399,570,305,024.00 |
![]() | Roche Holding AG - Cogs Excluding Depreciation and Amortization | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Cogs Excluding Depreciation and Amortization | 280,205,508,085.11 |